{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:48:44Z","timestamp":1782902924653,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271438"],"award-info":[{"award-number":["82271438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Science and Technology Major Project","award":["KJZD20230923114307015"],"award-info":[{"award-number":["KJZD20230923114307015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08483-6","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:27:26Z","timestamp":1782124046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose MyoAAV 2A-mediated delivery of engineered micro-utrophin achieves pan- muscle tissue distribution with elevated muscle function in Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"24","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikai","family":"Xiahou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"8483_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1083\/jcb.122.4.809","volume":"122","author":"JM Ervasti","year":"1993","unstructured":"Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 1993;122:809\u201323.","journal-title":"J Cell Biol"},{"key":"8483_CR2","doi-asserted-by":"crossref","unstructured":"Watchko JF, O\u2019Day TL, Hoffman EP. Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol (Bethesda Md : 1985). 2002;93:407\u201317.","DOI":"10.1152\/japplphysiol.01242.2001"},{"key":"8483_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda Si, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Reviews Disease Primers. 2021;7:13.","journal-title":"Nat Reviews Disease Primers"},{"key":"8483_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","volume":"20","author":"DR Asher","year":"2020","unstructured":"Asher DR, Thapa K, Dharia SD, et al. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20:263\u201374.","journal-title":"Expert Opin Biol Ther"},{"key":"8483_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene Moxeparvovec: First Approval. Drugs. 2023;83:1323\u20139.","journal-title":"Drugs"},{"key":"8483_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020;77:1122\u201331.","journal-title":"JAMA Neurol"},{"key":"8483_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Therapy: J Am Soc Gene Therapy. 2021;29:464\u201388.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"8483_CR8","unstructured":"Pfizer Inc. Pfizer\u2019s new Phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal Phase 3 study. 2020. https:\/\/investors.pfizer.com\/Investors\/News\/news-details\/2020\/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study-05-15"},{"key":"8483_CR9","unstructured":"Biosciences S. Letter to the duchenne community: update on SGT-001 phase I\/II clinical hold for IGNITE DMD program. 2020. https:\/\/www.solidbio.com\/about\/media\/news\/letter-to-the-duchenne-community-update-on-sgt-001-phase-i-ii-clinical-hold-for-ignite-dmd-program"},{"key":"8483_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/mt.2010.94","volume":"18","author":"JN Kornegay","year":"2010","unstructured":"Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Therapy: J Am Soc Gene Therapy. 2010;18:1501\u20138.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"8483_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, et al. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther. 2018;29:285\u201398.","journal-title":"Hum Gene Ther"},{"key":"8483_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice. Mol Therapy: J Am Soc Gene Therapy. 2018;26:664\u20138.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"8483_CR13","doi-asserted-by":"crossref","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184.","DOI":"10.1016\/j.cell.2021.08.028"},{"key":"8483_CR14","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","volume":"29","author":"DA Dalwadi","year":"2021","unstructured":"Dalwadi DA, Calabria A, Tiyaboonchai A, et al. AAV integration in human hepatocytes. Mol Therapy: J Am Soc Gene Therapy. 2021;29:2898\u2013909.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"8483_CR15","doi-asserted-by":"crossref","unstructured":"Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225.","DOI":"10.1016\/j.jpeds.2020.05.044"},{"key":"8483_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/339055a0","volume":"339","author":"DR Love","year":"1989","unstructured":"Love DR, Hill DF, Dickson G, et al. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature. 1989;339:55\u20138.","journal-title":"Nature"},{"key":"8483_CR17","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1083\/jcb.115.6.1695","volume":"115","author":"TM Nguyen","year":"1991","unstructured":"Nguyen TM, Ellis JM, Love DR, et al. Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J Cell Biol. 1991;115:1695\u2013700.","journal-title":"J Cell Biol"},{"key":"8483_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/sj.gt.3301066","volume":"7","author":"PM Wakefield","year":"2000","unstructured":"Wakefield PM, Tinsley JM, Wood MJ, Gilbert R, Karpati G, Davies KE. Prevention of the dystrophic phenotype in dystrophin\/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther. 2000;7:201\u20134.","journal-title":"Gene Ther"},{"key":"8483_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4:1441\u20134.","journal-title":"Nat Med"},{"key":"8483_CR20","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1093\/hmg\/11.26.3333","volume":"11","author":"S Squire","year":"2002","unstructured":"Squire S, Raymackers JM, Vandebrouck C, et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet. 2002;11:3333\u201344.","journal-title":"Hum Mol Genet"},{"key":"8483_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/ng0598-79","volume":"19","author":"JA Rafael","year":"1998","unstructured":"Rafael JA, Tinsley JM, Potter AC, Deconinck AE, Davies KE. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet. 1998;19:79\u201382.","journal-title":"Nat Genet"},{"key":"8483_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","volume":"90","author":"AE Deconinck","year":"1997","unstructured":"Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997;90:717\u201327.","journal-title":"Cell"},{"key":"8483_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/384349a0","volume":"384","author":"JM Tinsley","year":"1996","unstructured":"Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 1996;384:349\u201353.","journal-title":"Nature"},{"key":"8483_CR24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Morales L, Malik AS, et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med. 2019;25:1505\u201311.","journal-title":"Nat Med"},{"key":"8483_CR25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41586-024-08310-2","volume":"637","author":"L Wan","year":"2025","unstructured":"Wan L, Ge X, Xu Q, et al. Structure and assembly of the dystrophin glycoprotein complex. Nature. 2025;637:1252\u201360.","journal-title":"Nature"},{"key":"8483_CR26","doi-asserted-by":"publisher","first-page":"18153","DOI":"10.1074\/jbc.M111.284521","volume":"287","author":"G Acsadi","year":"2012","unstructured":"Acsadi G, Moore SA, Ch\u00e9ron A, et al. Novel mutation in spectrin-like repeat 1 of dystrophin central domain causes protein misfolding and mild Becker muscular dystrophy. J Biol Chem. 2012;287:18153\u201362.","journal-title":"J Biol Chem"},{"key":"8483_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41598-022-04892-x","volume":"12","author":"AV Starikova","year":"2022","unstructured":"Starikova AV, Skopenkova VV, Polikarpova AV, et al. Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression. Sci Rep. 2022;12:848.","journal-title":"Sci Rep"},{"key":"8483_CR28","first-page":"1089","volume":"22","author":"NC Voermans","year":"2023","unstructured":"Voermans NC, Ferreiro A, Aartsema-Rus A, Jungbluth H. Gene therapy for X-linked myotubular myopathy: the challenges. The Lancet. Neurology. 2023;22:1089\u201391.","journal-title":"Neurology"},{"key":"8483_CR29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31:332\u201341.","journal-title":"Nat Med"},{"key":"8483_CR30","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D, Systemic AAV. Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Therapy: J Am Soc Gene Therapy. 2018;26:2337\u201356.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"8483_CR31","first-page":"904","volume":"18","author":"Using utrophin to treat DMD","year":"2019","unstructured":"Using utrophin to treat DMD. Nat Rev Drug Discov. 2019;18:904.","journal-title":"Nat Rev Drug Discov"},{"key":"8483_CR32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N Engl J Med. 2010;363:1429\u201337.","journal-title":"N Engl J Med"},{"key":"8483_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1006\/jmbi.2000.3583","volume":"297","author":"CA Moores","year":"2000","unstructured":"Moores CA, Keep NH, Kendrick-Jones J. Structure of the utrophin actin-binding domain bound to F-actin reveals binding by an induced fit mechanism. J Mol Biol. 2000;297:465\u201380.","journal-title":"J Mol Biol"},{"key":"8483_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.fmre.2022.07.004","volume":"2","author":"R Wu","year":"2022","unstructured":"Wu R, Song Y, Wu S, Chen Y. Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. Fundamental Res. 2022;2:885\u201393.","journal-title":"Fundamental Res"},{"key":"8483_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/JND-200622","volume":"8","author":"G Cooper-Olson","year":"2021","unstructured":"Cooper-Olson G, Rodino-Klapac LR, Potter RA. Evaluation of the Lipid-binding Properties of Recombinant Dystrophin Spectrin-like Repeat Domains R1-3. J Neuromuscul Dis. 2021;8:489\u201394.","journal-title":"J Neuromuscul Dis"},{"key":"8483_CR36","doi-asserted-by":"crossref","unstructured":"Kennedy TL, Guiraud S, Edwards B, et al. Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2\/mdx mice. Mol Therapy Methods Clin Dev. 2018;11.","DOI":"10.1016\/j.omtm.2018.10.005"},{"key":"8483_CR37","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/mt.2008.149","volume":"16","author":"GL Odom","year":"2008","unstructured":"Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice. Mol Therapy: J Am Soc Gene Therapy. 2008;16:1539\u201345.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"8483_CR38","doi-asserted-by":"publisher","first-page":"e1000083","DOI":"10.1371\/journal.pmed.1000083","volume":"6","author":"KJ Sonnemann","year":"2009","unstructured":"Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA, Ervasti JM. Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med. 2009;6:e1000083.","journal-title":"PLoS Med"},{"key":"8483_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0092-8674(00)80533-4","volume":"90","author":"RM Grady","year":"1997","unstructured":"Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 1997;90:729\u201338.","journal-title":"Cell"},{"key":"8483_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","volume":"72","author":"A \u0141oboda","year":"2020","unstructured":"\u0141oboda A, Dulak J. Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep. 2020;72:1227\u201363.","journal-title":"Pharmacol Rep"},{"key":"8483_CR41","doi-asserted-by":"publisher","first-page":"15457","DOI":"10.1074\/jbc.R200031200","volume":"278","author":"DE Michele","year":"2003","unstructured":"Michele DE, Campbell KP. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem. 2003;278:15457\u201360.","journal-title":"J Biol Chem"},{"key":"8483_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12576-020-00768-9","volume":"70","author":"Y Kitajima","year":"2020","unstructured":"Kitajima Y, Yoshioka K, Suzuki N. The ubiquitin-proteasome system in regulation of the skeletal muscle homeostasis and atrophy: from basic science to disorders. J Physiol Sci. 2020;70:40.","journal-title":"J Physiol Sci"},{"key":"8483_CR43","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1073\/pnas.83.11.3860","volume":"83","author":"JB Miller","year":"1986","unstructured":"Miller JB, Stockdale FE. Developmental origins of skeletal muscle fibers: clonal analysis of myogenic cell lineages based on expression of fast and slow myosin heavy chains. Proc Natl Acad Sci USA. 1986;83:3860\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8483_CR44","doi-asserted-by":"publisher","first-page":"e1009179","DOI":"10.1371\/journal.pgen.1009179","volume":"16","author":"GB Banks","year":"2020","unstructured":"Banks GB, Chamberlain JS, Odom GL. Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. PLoS Genet. 2020;16:e1009179.","journal-title":"PLoS Genet"},{"key":"8483_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1756-6606-7-17","volume":"7","author":"J-H Choi","year":"2014","unstructured":"Choi J-H, Yu N-K, Baek G-C, et al. Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol Brain. 2014;7:17.","journal-title":"Mol Brain"},{"key":"8483_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omtm.2018.05.005","volume":"10","author":"Y Wu","year":"2018","unstructured":"Wu Y, Jiang L, Geng H, et al. A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae. Mol Therapy Methods Clin Dev. 2018;10:38\u201347.","journal-title":"Mol Therapy Methods Clin Dev"},{"issue":"10","key":"8483_CR47","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.cell.2023.03.033","volume":"11","author":"SM Hindi","year":"2023","unstructured":"Hindi SM, Petrany MJ, Greenfeld E, et al. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. Cell. 2023;11(10):2062\u2013e207717.","journal-title":"Cell"},{"key":"8483_CR48","doi-asserted-by":"publisher","first-page":"110939","DOI":"10.1016\/j.celrep.2022.110939","volume":"39","author":"J Zheng","year":"2022","unstructured":"Zheng J, Lou J, Li Y, et al. Satellite cell-specific deletion of Cipc alleviates myopathy in mdx mice. Cell Rep. 2022;39:110939.","journal-title":"Cell Rep"},{"key":"8483_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2017.01.040","volume":"16","author":"C Shen","year":"2017","unstructured":"Shen C, Zhou J, Wang X, et al. Angiotensin-II-induced Muscle Wasting is Mediated by 25-Hydroxycholesterol via GSK3\u03b2 Signaling Pathway. EBioMedicine. 2017;16:238\u201350.","journal-title":"EBioMedicine"},{"key":"8483_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1172\/JCI81655","volume":"126","author":"SM Hindi","year":"2016","unstructured":"Hindi SM, Kumar A. TRAF6 regulates satellite stem cell self-renewal and function during regenerative myogenesis. J Clin Investig. 2016;126:151\u201368.","journal-title":"J Clin Investig"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08483-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:23:21Z","timestamp":1782901401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08483-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8483"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08483-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were authorized by the Ethics Committee of Sports Science Experiments, Beijing Sport University (Approval No. 2022029\u00a0A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"834"}}